Japanese encephalitis (JE) is a viral infection that spreads by mosquito bites, causing brain inflammation and swelling due to bacterial or viral infections in the brain. The sign and symptoms of Japanese encephalitis infections are mild in nature such as fever and headache. The severe form of Japanese encephalitis is characterized by symptoms such as rapid onset of coma, disorientation, high fever, headache, neck stiffness, seizures, spastic paralysis and ultimately death. The confirmatory diagnosis of JEV infection requires a laboratory testing of serum or preferentially, cerebrospinal fluid to detect virus-specific Immunoglobulin M (IgM) antibodies. Spring Bank Pharmaceuticals, Inc. is in the process of developing SB 9200, which is in the discovery stage of development for the treatment of Japanese encephalitis. Some of the companies developing drugs for the treatment of Japanese encephalitis are Ennaid Therapeutics, LLC, Panacea Biotec Ltd., VABIOTECH and others.
JAPANESE ENCEPHALITIS THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
As of October 2017, the Japanese encephalitis therapeutics pipeline comprises of 12 drug candidates in different stages of development.
Some of the key players developing drugs for the treatment of Japanese encephalitis include Shandong Hengye Biotech, Co. Ltd., Panacea Biotec Ltd., and Ennaid Therapeutics, LLC.
Scope for Customization
P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:
Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles